Ioversol

Ioversol (CAS No.: 87771-40-2) is a synthetic small molecule classified as a nonionic iodinated contrast agent and is primarily used as an imaging research reagent in preclinical radiographic workflows, where its high X ray attenuation supports contrast enhancement for computed tomography and related X ray based visualization in biological systems. In life sciences research, it is generally positioned within the molecular imaging and translational pharmacology toolkit rather than as a direct pathway modulator, with its functional profile arising predominantly from physicochemical radiodensity effects in extracellular and vascular compartments instead of canonical receptor binding or enzyme inhibition; accordingly, no well established primary protein target or dedicated intracellular signaling pathway is typically assigned in standard target based screening frameworks. Available research descriptions indicate utility in animal imaging studies, including CT or X ray protocols, and reports from experimental settings note use in contexts where blood brain barrier integrity is preserved under appropriate study conditions, supporting applications in model characterization, anatomical delineation, and imaging method optimization. Because this agent is not commonly developed as a potency driven bioactive modulator in cell based pharmacology panels, quantitative in vitro activity metrics such as IC50, EC50, or MIC are often not reported in conventional nanomolar to micromolar target engagement terms, and investigators generally evaluate performance through imaging contrast outcomes, distribution behavior, and exposure dependent signal quality. Typical research uses include cell and tissue compatibility assessments, imaging protocol development, and in vivo contrast enhanced visualization in animal models for biodistribution analysis or preclinical assay calibration, while the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.